Compare Stocks: TLSI, IART, TNDM, and BVS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BVS Bioventus	$13.81 +2.1%	$13.51	$6.26 ▼ $15.89	$1.16B	0.65	472,899 shs	455,410 shs
IART Integra LifeSciences	$16.12 +1.5%	$17.03	$8.70 ▼ $20.49	$1.25B	1.21	884,934 shs	539,025 shs
TLSI TriSalus Life Sciences	$4.34 -5.9%	$4.90	$2.20 ▼ $7.95	$267.24M	0.44	419,101 shs	350,984 shs
TNDM Tandem Diabetes Care	$15.72 +3.3%	$19.67	$11.46 ▼ $29.65	$1.09B	1.55	1.87 million shs	2.84 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BVS Bioventus	0.00%	+6.97%	+0.15%	+41.21%	+100.44%
IART Integra LifeSciences	0.00%	+5.91%	-4.33%	-14.07%	+15.89%
TLSI TriSalus Life Sciences	0.00%	-14.90%	-11.97%	-8.25%	-10.33%
TNDM Tandem Diabetes Care	0.00%	-6.82%	-26.54%	-3.20%	+24.37%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BVS Bioventus	$13.81 +2.1%	$13.51	$6.26 ▼ $15.89	$1.16B	0.65	472,899 shs	455,410 shs
IART Integra LifeSciences	$16.12 +1.5%	$17.03	$8.70 ▼ $20.49	$1.25B	1.21	884,934 shs	539,025 shs
TLSI TriSalus Life Sciences	$4.34 -5.9%	$4.90	$2.20 ▼ $7.95	$267.24M	0.44	419,101 shs	350,984 shs
TNDM Tandem Diabetes Care	$15.72 +3.3%	$19.67	$11.46 ▼ $29.65	$1.09B	1.55	1.87 million shs	2.84 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BVS Bioventus	0.00%	+6.97%	+0.15%	+41.21%	+100.44%
IART Integra LifeSciences	0.00%	+5.91%	-4.33%	-14.07%	+15.89%
TLSI TriSalus Life Sciences	0.00%	-14.90%	-11.97%	-8.25%	-10.33%
TNDM Tandem Diabetes Care	0.00%	-6.82%	-26.54%	-3.20%	+24.37%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BVS Bioventus	2.83	Moderate Buy	$16.80	21.65% Upside
IART Integra LifeSciences	1.88	Reduce	$18.86	16.98% Upside
TLSI TriSalus Life Sciences	2.40	Hold	$10.20	135.02% Upside
TNDM Tandem Diabetes Care	2.48	Hold	$29.18	85.65% Upside

Current Analyst Ratings Breakdown

Latest TLSI, IART, TNDM, and BVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	TNDM Tandem Diabetes Care	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$31.00 ➝ $28.00
9/23/2026	TLSI TriSalus Life Sciences	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$12.00
9/23/2026	TLSI TriSalus Life Sciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$12.00
9/23/2026	TLSI TriSalus Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$11.00 ➝ $12.00
9/10/2026	TLSI TriSalus Life Sciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/9/2026	TLSI TriSalus Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
9/9/2026	TLSI TriSalus Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
9/8/2026	TNDM Tandem Diabetes Care	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/21/2026	TNDM Tandem Diabetes Care	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
8/17/2026	BVS Bioventus	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$15.00 ➝ $19.00
8/17/2026	BVS Bioventus	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$15.00

(Data available from 9/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BVS Bioventus	$568.09M	2.04	$1.28 per share	10.83	$2.76 per share	5.00
IART Integra LifeSciences	$1.65B	0.76	$4.22 per share	3.82	$13.40 per share	1.20
TLSI TriSalus Life Sciences	$45.15M	5.92	N/A	N/A	($0.68) per share	-6.38
TNDM Tandem Diabetes Care	$1.04B	1.05	N/A	N/A	$2.29 per share	6.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BVS Bioventus	$22.73M	$0.77	17.94	15.52	1.76	9.36%	28.08%	9.82%	N/A
IART Integra LifeSciences	-$516.47M	-$0.09	N/A	6.27	0.83	-0.44%	18.30%	5.30%	10/29/2026 (Estimated)
TLSI TriSalus Life Sciences	-$39.23M	-$1.30	N/A	N/A	N/A	-62.59%	N/A	-64.47%	11/12/2026 (Estimated)
TNDM Tandem Diabetes Care	-$204.71M	-$0.93	N/A	157.20	N/A	-6.08%	-45.97%	-6.23%	11/5/2026 (Estimated)

Latest TLSI, IART, TNDM, and BVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	TLSI TriSalus Life Sciences	-$0.1550	-$0.16	-$0.0050	-$0.16	$10.27 million	$11.41 million
8/6/2026	Q2 2026	TNDM Tandem Diabetes Care	-$0.3207	-$0.31	+$0.0107	-$0.31	$254.99 million	$254.56 million
8/5/2026	Q2 2026	BVS Bioventus	$0.22	$0.22	N/A	$0.47	N/A	$153.21 million
7/29/2026	Q2 2026	IART Integra LifeSciences	$0.4805	$0.56	+$0.0795	$0.06	$417.54 million	$418.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BVS Bioventus	N/A	N/A	N/A	N/A	N/A
IART Integra LifeSciences	N/A	N/A	N/A	N/A	N/A
TLSI TriSalus Life Sciences	N/A	N/A	N/A	N/A	N/A
TNDM Tandem Diabetes Care	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BVS Bioventus	0.83	1.69	1.17
IART Integra LifeSciences	1.75	3.60	2.11
TLSI TriSalus Life Sciences	5.05	5.35	4.97
TNDM Tandem Diabetes Care	4.62	3.18	2.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BVS Bioventus	62.94%
IART Integra LifeSciences	84.78%
TLSI TriSalus Life Sciences	2.58%
TNDM Tandem Diabetes Care	N/A

Insider Ownership

Company	Insider Ownership
BVS Bioventus	33.50%
IART Integra LifeSciences	3.84%
TLSI TriSalus Life Sciences	16.30%
TNDM Tandem Diabetes Care	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BVS Bioventus	950	84.09 million	55.92 million	N/A
IART Integra LifeSciences	4,427	77.77 million	74.79 million	Optionable
TLSI TriSalus Life Sciences	102	61.58 million	51.54 million	Not Optionable
TNDM Tandem Diabetes Care	2,500	69.58 million	68.12 million	Optionable

TLSI, IART, TNDM, and BVS Headlines

Recent News About These Companies

Tandem Diabetes Care(TNDM)获机构维持买入评级，目标价下调至28美元

September 26 at 5:26 PM | eeo.com.cnE

Tandem Diabetes Care (NASDAQ:TNDM) Stock Falls 6.7% After Analyst Downgrade

September 26 at 2:24 AM | americanbankingnews.com

Tandem Diabetes Care (NASDAQ:TNDM) Stock Price Target Cut by Truist Financial

September 26 at 1:42 AM | americanbankingnews.com

Tandem Diabetes Care (NASDAQ:TNDM) Stock Price Down 6.7% After Analyst Downgrade

September 24 at 2:39 PM | marketbeat.com

Tandem Diabetes Care (NASDAQ:TNDM) Given New $28.00 Price Target at Truist Financial

September 24 at 12:23 PM | marketbeat.com

Truist Lowers Price Target on Tandem Diabetes Care to $28 From $31, Keeps Buy Rating

September 24 at 8:05 AM | marketscreener.comM

Is Tandem Diabetes Care (TNDM) Undervalued As Investors Weigh Its 34% One Year Return?

September 20, 2026 | finance.yahoo.com

Engineers Gate Manager LP Makes New Investment in Tandem Diabetes Care, Inc. $TNDM

September 20, 2026 | marketbeat.com

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Rating of "Hold" from Brokerages

September 18, 2026 | marketbeat.com

Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?

September 17, 2026 | zacks.com

Tandem Diabetes Care (NASDAQ:TNDM) Shares Up 5.6% - Should You Buy?

September 16, 2026 | marketbeat.com

Squarepoint Ops LLC Buys Shares of 217,386 Tandem Diabetes Care, Inc. $TNDM

September 13, 2026 | marketbeat.com

Tandem Diabetes Care (NASDAQ:TNDM) Stock Price Down 4.2% - Here's What Happened

September 11, 2026 | marketbeat.com

Tandem Diabetes Care: Stop Paying For Tomorrow's Profits - Strong Sell

September 11, 2026 | seekingalpha.com

Is Tandem Diabetes Care Inc (TNDM) a Bargain After 4.2% Drop? GF Value Says Undervalued

September 10, 2026 | gurufocus.com

First Light Asset Management LLC Boosts Position in Tandem Diabetes Care, Inc. $TNDM

September 10, 2026 | marketbeat.com

Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now

September 9, 2026 | zacks.com

Wellington Management Group LLP Has $13.16 Million Holdings in Tandem Diabetes Care, Inc. $TNDM

September 8, 2026 | marketbeat.com

Tandem Diabetes Care (NASDAQ:TNDM) Share Price Passes Above 200 Day Moving Average - Here's What Happened

September 3, 2026 | marketbeat.com

Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics

August 21, 2026 | benzinga.com

Tandem Diabetes Care (TNDM) Receives a Buy from Lake Street

August 16, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSI, IART, TNDM, and BVS Company Descriptions

Bioventus NASDAQ:BVS

$13.81 +0.29 (+2.14%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$13.75 -0.06 (-0.43%)

As of 09/25/2026 07:30 PM Eastern

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Integra LifeSciences NASDAQ:IART

$16.12 +0.24 (+1.51%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$16.12 0.00 (0.00%)

As of 09/25/2026 07:30 PM Eastern

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

TriSalus Life Sciences NASDAQ:TLSI

$4.34 -0.27 (-5.86%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$4.34 0.00 (-0.12%)

As of 09/25/2026 07:30 PM Eastern

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

Tandem Diabetes Care NASDAQ:TNDM

$15.72 +0.50 (+3.29%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$16.07 +0.35 (+2.19%)

As of 09/25/2026 07:30 PM Eastern

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TLSI, IART, TNDM, and BVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TLSI, IART, TNDM, and BVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TLSI, IART, TNDM, and BVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSI, IART, TNDM, and BVS Company Descriptions

Bioventus NASDAQ:BVS

Integra LifeSciences NASDAQ:IART

TriSalus Life Sciences NASDAQ:TLSI

Tandem Diabetes Care NASDAQ:TNDM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TLSI, IART, TNDM, and BVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TLSI, IART, TNDM, and BVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TLSI, IART, TNDM, and BVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSI, IART, TNDM, and BVS Company Descriptions

Bioventus NASDAQ:BVS

Integra LifeSciences NASDAQ:IART

TriSalus Life Sciences NASDAQ:TLSI

Tandem Diabetes Care NASDAQ:TNDM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools